Insider buying last 90 days
No open-market insider purchases were filed for ACAD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ACAD insider filing, plotted on the chart in Gekko.Open ACAD in Gekko
NASDAQ: ACAD
ACADIA Pharmaceuticals (ACAD) Stock Analysis & Forecast
Oct 12 close
$19.41−0.37 (−1.9%)
Gekko Brief
AI summaryOct 12 closeACADIA shares have been under pressure amid an ongoing investigation by Bronstein, Gewirtz & Grossman into a prior price drop, alongside a mix of analyst actions. Argus lowered its target to $19.00, while RBC Capital maintained its Outperform rating but cut its target from $42 to $36 and then again from $37.00 to $36.00. BofA Securities reiterated a Buy rating with a $31 target. Coverage has also pointed to pricing risk and pipeline execution concerns, even as Q2 2026 revenue rose, with DAYBUE and NUPLAZID both contributing to growth.
ACAD closed at $19.41, down 1.9%, with its price sitting below both the 50-day average of $26.22 and the 200-day average of $24.17. The stock's one-month return stands at -30.3% and its three-month return at -23.9%. The GekkoIndex reads 71.4, placing it in the Buying zone, while the gap to Gekko Fair Value of $28.54 stands at -32%.
Earnings are scheduled for 4 November 2026, 23 days away, falling within the next 20 trading days. Over the last 30 days, there has been 1 unusual options signal, with put premium of $1,302,030 against call premium of $641,039. Seasonality over the past 5 years shows an average 20-day return of 4.7% from this point in the calendar, rising in 4 of those years. Analyst consensus across 16 firms includes 12 buy and 4 hold ratings, with a consensus target of $31.95.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
ACADIA Pharmaceuticals price vs fair value
Close $19.41200-day averageGekko Fair Value $28.54
ACADIA Pharmaceuticals quick facts
- Market cap
- $3.32B
- P/E ratio
- 8.8
- Forward P/E
- 25.2
- EPS, TTM
- $2.22
- Revenue, TTM
- $1.14B
- Profit margin
- 33.4%
- Dividend yield
- —
- Beta
- 0.89
- Volume
- 1.18M avg 2.45M
- 1-year return
- −5.9%
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±8.8%
- 50-day average
- $26.22
- 200-day average
- $24.17
- Next earnings
- Nov 4 after close
- Shares outstanding
- 172.3M
ACADIA Pharmaceuticals swing-trade checklist
ACADIA Pharmaceuticals scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $19.41 sits between the 50-day ($26.22) and 200-day ($24.17) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
71.4, Buying
Reading 71.4 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
32.0% below
Price is 32% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.7% on average
From this point in the calendar, the next 20 trading days averaged +4.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
ACADIA Pharmaceuticals stock chart and price history
ACADIA Pharmaceuticals closed at $19.41 on Oct 12, 2026, −5.9% over the past year, inside a 52-week range of $19.32 to $30.96.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −30.3%
- 3 months
- −23.9%
- 6 months
- −9.6%
- 1 year
- −5.9%
The full ACAD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ACAD in Gekko
Follow ACADIA Pharmaceuticals through every session
Put ACAD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ACAD in GekkoFree for 7 days. No credit card required.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals works on small molecule medicines aimed at disorders of the central nervous system. Its best-known product is NUPLAZID (pimavanserin), prescribed to treat hallucinations and delusions tied to psychosis in Parkinson's disease patients. Beyond this approved treatment, the company is known for its focus on conditions affecting the brain and nervous system more broadly.
The company's pipeline extends well past its marketed drug. Pimavanserin itself is being studied further in Phase 3 trials for Alzheimer's disease psychosis and for negative symptoms of schizophrenia. Trofinetide, a synthetic compound, is in Phase 3 testing for Rett syndrome, while ACP-044, a non-opioid pain treatment taken orally, is in Phase 2 studies covering both acute and chronic pain. A fourth candidate, ACP-319, targets muscarinic receptors and is in early Phase 1 testing for schizophrenia and cognitive improvement in Alzheimer's patients.
ACADIA Pharmaceuticals was founded in 1993 and is based in San Diego, California. Its shares trade on the NASDAQ under the ticker ACAD.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- acadia.com
ACADIA Pharmaceuticals GekkoIndex: the smart money zone
ACADIA Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.4, in the Buying zone, down 6.6 points over five sessions.
71.4Buying
Down 6.6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 61 | −1.2% | −6.1% | ||
| Accumulation | 238 | −0.9% | +1.4% | ||
| Neutral | 348 | +0.8% | +1.0% | ||
| Distribution | 34 | −0.7% | −1.5% | ||
| Selling | 1 | Too few readings yet | |||
Average ACAD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the ACAD price, zone by zone.Track ACAD in Gekko
Is ACADIA Pharmaceuticals stock overvalued? Gekko Fair Value
ACADIA Pharmaceuticals trades 32.0% below Gekko Fair Value of $28.54, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ACADIA Pharmaceuticals shares are worth, recalculated every trading day.
$28.54
Gekko Fair Value, Oct 10, 2026
32.0% Undervalued
At the end of Aug 2026 the price was 8.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ACAD in Gekko
ACADIA Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for ACADIA Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ACAD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ACAD, plotted on the chart in Gekko.Open ACAD in Gekko
Unusual options activity last 30 days
1signal, 33% of the flagged premium in calls.
Latest: Bullish flow on Sep 22, $1.94M in unusual premium.
Every signal with its contract, strike and premium.Unlock in Gekko
ACADIA Pharmaceuticals earnings: next date and track record
ACADIA Pharmaceuticals reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- $0.20
- Revenue estimate
- $332.8M
5 of 8reports beat the EPS estimate
±6.3%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- ACADIA reported Q2 2026 total revenues of $308 million, up 17% year-over-year. DAYBUE net sales reached $125 million (+30% YoY), driven by DAYBUE STIX launch adoption, while NUPLAZID delivered $183 million (+10% YoY adjusted). CHMP issued positive opinion for DAYBUE in Europe. Phase II remlifanserin readout for Alzheimer's disease psychosis expected September-October 2026, with estimated $4 billion peak sales potential.
- Guidance
- ACADIA raised 2026 DAYBUE guidance to $480-$510 million. Long-term targets include $700 million in DAYBUE sales and ~$1 billion in NUPLAZID net sales by 2028. Remlifanserin Phase II top-line results expected September-October 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.18 est $0.07 | $308.0M est $296.6M | +12.5% |
| May 6, 2026 | $0.02 est $0.08 | $268.1M est $280.3M | +0.9% |
| Feb 25, 2026 | $0.14 est $0.14 | $284.0M est $292.8M | +0.2% |
| Nov 5, 2025 | $0.26 est $0.14 | $278.6M est $292.6M | −0.9% |
| Aug 6, 2025 | $0.16 est $0.14 | $264.6M est $262.0M | +3.2% |
| May 7, 2025 | $0.11 est $0.11 | $244.3M est $239.0M | +16.4% |
| Feb 26, 2025 | $0.86 est $0.22 | $259.6M est $273.0M | +1.7% |
| Nov 6, 2024 | $0.20 est $0.14 | $250.4M est $282.9M | +14.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
ACADIA Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for ACADIA Pharmaceuticals is $31.95, +64.6% from the last close, from 16 firms rating the stock in the last 90 days.
$31.95consensus 12-month target, +64.6% from the last close
Now $19.41Avg $31.95
Low $25High $49
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | BMO Capital | $34 | +75.2% |
| Oct 9 | Bank of America Securities | $31 | +59.7% |
| Oct 8 | RBC Capital | $36 | +85.5% |
| Oct 5 | RBC Capital | $37 | +90.6% |
| Sep 25 | H.C. Wainwright | $33 | +70.0% |
−6.1%average 20-day move after past Buying readings
+4.7%average move over the next 20 trading days in the last 5 years
±4.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
ACADIA Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, ACADIA Pharmaceuticals averaged +4.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 3 of 5 |
| Next 10 trading days | +0.4% | 1 of 5 |
| Next 15 trading days | +5.6% | 3 of 5 |
| Next 20 trading days | +4.7% | 4 of 5 |
| Next 30 trading days | +5.5% | 3 of 5 |
For scale, ACAD’s typical 20-trading-day move in either direction is about 8.8%.
ACADIA Pharmaceuticals market cap and key statistics
ACADIA Pharmaceuticals’s market cap is $3.32B, with a P/E ratio of 8.8 and revenue of $1.14B over the last twelve months.
Valuation
- Market cap
- $3.32B
- P/E ratio
- 8.8
- Forward P/E
- 25.2
- EPS, TTM
- $2.22
- Gekko Fair Value
- $28.54
Trading
- Volume
- 1.18M
- Avg volume, 20 days
- 2.45M
- 52-week high
- $30.96
- 52-week low
- $19.32
- Shares outstanding
- 172.3M
Financials
- Revenue, TTM
- $1.14B
- Profit margin
- 33.4%
- Return on equity
- 35.7%
- Quarterly earnings growth, YoY
- +13.3%
Risk and income
- Beta
- 0.89
- Typical daily move
- ±4.8%
- Typical 20-day move
- ±8.8%
ACADIA Pharmaceuticals stock news this week
Coverage of ACADIA Pharmaceuticals this week reads positive: 6 positive, 5 neutral and 4 negative headlines.
- Bronstein, Gewirtz & Grossman, LLC Is Investigating ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Investors to ConnectACCESS Newswire, Oct 12
- Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)Defense World, Oct 12
- ACADIA Pharmaceuticals Inc. (ACAD) Stock ForecastsYahoo! Finance Canada, Oct 11
- BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $31Moomoo, Oct 10
- Why Acadia Pharmaceuticals Bears Were Right Before The DropSimply Wall Street, Oct 10
- Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Assembly Biosciences (ASMB)The Globe and Mail, Oct 10
ACADIA Pharmaceuticals peers
ACADIA Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
ACADIA Pharmaceuticals stock FAQ
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.32B at the Oct 12, 2026 close of $19.41, with 172.3M shares outstanding. The shares trade on a P/E ratio of 8.8.
What is the ACADIA Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for ACADIA Pharmaceuticals is $31.95, +64.6% from the last close. Of the 16 firms that rated the stock in the last 90 days, 12 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is ACADIA Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate ACADIA Pharmaceuticals is undervalued: the Oct 12, 2026 close of $19.41 is 32.0% below Gekko Fair Value of $28.54. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does ACADIA Pharmaceuticals report earnings next?
ACADIA Pharmaceuticals is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of $0.20 per share on revenue of $332.8M. ACADIA Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 6.3% on average across the report.
What is ACADIA Pharmaceuticals’s 52-week high and low?
ACADIA Pharmaceuticals’s 52-week high is $30.96 and its 52-week low is $19.32; it closed at $19.41 on Oct 12, 2026, −5.9% over the past year. Over the last five years the shares peaked at $33.99 on Jul 18, 2023.
Is ACADIA Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 2 as headwinds (smart money and earnings risk). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in ACADIA Pharmaceuticals?
Gekko flagged 1 unusual options signal in ACADIA Pharmaceuticals over the last 30 days, with $641K of flagged premium in calls and $1.30M in puts. The latest, bullish flow, was on Sep 22, 2026 with $1.94M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See ACADIA Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.